Idera Pharmaceuticals Inc (IDRA) - Financial and Strategic SWOT Analysis Review

Idera Pharmaceuticals Inc (IDRA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy Analysts summarization of the companys business strategy.
- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Idera Pharmaceuticals Inc. (Idera) is a clinical stage biopharmaceutical company, which focuses on the discovery, development and commercialization of novel nucleic acid therapeutic approach for the treatment of cancer and rare diseases. It is developing Toll-like receptor (TLR) agonist, tilsotolimod (IMO-2125) for the treatment of cancer. TLR agonists are key receptors of immune system and potential therapeutic target for various diseases. Its clinical-stage drug candidate, tilsotolimod, is an agonist of TLR9, in the phase III trials for the treatment of anti-PD1 refractory metastatic melanoma in combination with ipilimumab. Intratumoral tilsotolimod in combination with nivolumab is in the phase II trials for the treatment of multiple solid tumors. Idera is headquartered in Exton, Pennsylvania, the US.

Idera Pharmaceuticals Inc Key Recent Developments

Aug 08,2019: Idera Pharmaceuticals provides corporate update and reports second quarter 2019 financial results
May 02,2019: Idera Pharmaceuticals reports first quarter 2019 financial results and provides corporate update
Apr 10,2019: Idera Pharmaceuticals provides corporate update
Mar 06,2019: Idera Pharmaceuticals reports fourth quarter and year end 2018 financial results and provides corporate update
Dec 18,2018: Idera Pharmaceuticals announces appointment of Carol A. Schafer to its board of directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The companys core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


List of Tables
List of Figures
Section 1 - About the Company
Idera Pharmaceuticals Inc - Key Facts
Idera Pharmaceuticals Inc - Key Employees
Idera Pharmaceuticals Inc - Key Employee Biographies
Idera Pharmaceuticals Inc - Major Products and Services
Idera Pharmaceuticals Inc - History
Idera Pharmaceuticals Inc - Company Statement
Idera Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Section 2 Company Analysis
Company Overview
Idera Pharmaceuticals Inc - Business Description
Idera Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Idera Pharmaceuticals Inc - Strengths
Idera Pharmaceuticals Inc - Weaknesses
Idera Pharmaceuticals Inc - Opportunities
Idera Pharmaceuticals Inc - Threats
Idera Pharmaceuticals Inc - Key Competitors
Section 3 Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 Companys Lifesciences Financial Deals and Alliances
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Idera Pharmaceuticals Inc, Recent Deals Summary
Section 5 Companys Recent Developments
Aug 08, 2019: Idera Pharmaceuticals provides corporate update and reports second quarter 2019 financial results
May 02, 2019: Idera Pharmaceuticals reports first quarter 2019 financial results and provides corporate update
Apr 10, 2019: Idera Pharmaceuticals provides corporate update
Mar 06, 2019: Idera Pharmaceuticals reports fourth quarter and year end 2018 financial results and provides corporate update
Dec 18, 2018: Idera Pharmaceuticals announces appointment of Carol A. Schafer to its board of directors
Nov 06, 2018: Idera Pharmaceuticals reports third quarter 2018 financial results and provides corporate update
Sep 18, 2018: Idera Pharmaceuticals names Howard Pien as Board Director
Sep 11, 2018: Idera Pharmaceuticals announces corporate organizational changes
Aug 02, 2018: Idera Pharmaceuticals reports second quarter 2018 financial results and provides corporate update
Jul 16, 2018: Idera Pharmaceuticals Provides Update on Corporate Strategy and Outlook
Section 6 Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables


Idera Pharmaceuticals Inc, Key Facts
Idera Pharmaceuticals Inc, Key Employees
Idera Pharmaceuticals Inc, Key Employee Biographies
Idera Pharmaceuticals Inc, Major Products and Services
Idera Pharmaceuticals Inc, History
Idera Pharmaceuticals Inc, Key Competitors
Idera Pharmaceuticals Inc, Ratios based on current share price
Idera Pharmaceuticals Inc, Annual Ratios
Idera Pharmaceuticals Inc, Annual Ratios (Cont...1)
Idera Pharmaceuticals Inc, Interim Ratios
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Idera Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures


Idera Pharmaceuticals Inc, Performance Chart (2014 - 2018)
Idera Pharmaceuticals Inc, Ratio Charts
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

Idera Pharmaceuticals Inc (IDRA) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Idera Pharmaceuticals Inc. (Idera) is a clinical stage biopharmaceutical company, which focuses on the discovery, development and commercialization of drugs for the treatment of cancer and rare diseases. It develops

USD 250 View Report

Idera Pharmaceuticals Inc (IDRA) - Financial and Strategic SWOT Analysis Review

Idera Pharmaceuticals Inc (IDRA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by

USD 125 View Report

RespireRx Pharmaceuticals Inc (RSPI) - Strategic SWOT Analysis Review

RespireRx Pharmaceuticals Inc (RSPI) - Strategic SWOT Analysis Review provides a comprehensive insight into the companys history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis,

USD 125 View Report

Enzon Pharmaceuticals Inc (ENZN) - Strategic SWOT Analysis Review

Enzon Pharmaceuticals Inc (ENZN) - Strategic SWOT Analysis Review provides a comprehensive insight into the companys history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis,

USD 125 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available